Bavarian Nordic said it reached another milestone in its contract to supply the US government with its smallpox vaccine Imvamune, triggering a payment of $25 million. This brings to $100 million the amount the Kvistgard, Denmark-based company has received to date on the potential $1.6 billion contract.
Bavarian expects to receive another milestone payment of $25 million later in 2008. The Imvamune vaccine is designed for children, the elderly and people with compromised immune systems for whom a full strength smallpox vaccine would be unsuitable.
The company won the contract in a bitter battle with UK vaccines specialist Acambis plc, in which Acambis was accused of transgressing Bavarian’s intellectual property rights. The legal case was ended before it reached a resolution when Bavarian was awarded the contract in June 2007.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
